Correspondence 0001437749-25-037383 from Genprex, Inc. (GNPX)
Genprex, Inc.
Date: Dec. 10, 2025 · CIK: 0001595248 · Accession: 0001437749-25-037383
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291722
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance File No. 333-291722 Acceleration Request Requested Date: December 12, 2025 Requested Time: 4:05 p.m. , Eastern Time
Dear Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Genprex, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.
Please call Kate Basmagian of Lowenstein Sandler LLP at (646) 414-6941 to confirm the effectiveness of the Registration Statement or with any questions.
Sincerely,
GENPREX, INC.
Show Raw Text
CORRESP 1 filename1.htm gnpx20251208_corresp.htm December 10, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Re: Genprex, Inc. Registration Statement on Form S-1 File No. 333-291722 Acceleration Request Requested Date: December 12, 2025 Requested Time: 4:05 p.m. , Eastern Time Dear Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Genprex, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission. Please call Kate Basmagian of Lowenstein Sandler LLP at (646) 414-6941 to confirm the effectiveness of the Registration Statement or with any questions. Sincerely, GENPREX, INC. By: /s/ Ryan M. Confer Name: Ryan M. Confer Title: President, Chief Executive Officer and Chief Financial Officer